Pfizer CEO: Biden-backed Covid vaccine patent waiver will cause problems (cnbc.com) CNBC新闻 Today I Sent This Letter To Have a Candid Conversation With Our Colleagues About the Drivers of COVID-19 Access and Availability (linkedin.com) 这是他发在linkedin上面的致全体员工信的全文。提到了很多这两天大家的讨论内容，说上周已经present给过US Trade Representative了。 下面这个是我之前不知道的细节，不知道版上的牛人们之前是不是已经讨论过了： 2020年六月份的时候，Pfizer是提出了tiered pricing，富裕国家就是一份外卖价钱，这样政府可以买单让大家免费打，middle-income的国家是半价，low-income的国家是成本价，然后给很多最穷的地方会直接捐助。然后发生了什么呢？给这些国家提出tiered pricing的时候，问人家下不下订单，富裕国家爽快定了，其他绝大部分都没有，Pfizer很担心，还去一个个找那些非富裕国家的首脑们写信，打电话，甚至发短信，但是： However, most of them decided to place orders with other vaccine makers either because mRNA technology was untested at that time or because they were offered local production options. Some didn’t even approve our vaccine. Unfortunately, other vaccine producers were not able to meet their supply commitments for varying technical reasons. Most of the countries that did not choose us initially, came back and thanks to our phenomenal supply ramp up, we have started signing supply agreements with them. We expect the supply balance to weigh in their favor in the second half of 2021, and to have virtually enough supply for all in 2022. 这就是为什么现在看着疫苗都分配到富裕国家去的原因。
全文贴在这里，写的非常诚恳。建议大家读完全文。我挑了些重点画了一下。不好意思重点有点多。 更新：转发个122层WIBB的要点总结，写的超好： 要点总结： 2020 年6月开始辉瑞制定了价格体系。具体政策是富裕国价格高，中等国家便宜（基本为富裕国家的一半），穷国成本价，最穷的国家捐赠。 辉瑞开始联系了所有国家让他们提早订货，但只有少数富国下了订单，所以现在的大部分疫苗给了他们。辉瑞又联系了很多中低收入国家，但是大部分中低收入国家都与其他疫苗厂家订了货，辉瑞的MRNA技术也没有得到很多国家批准。但现在其他疫苗出了问题，所以这些国家又返回来订货，21年下半年供应会缓解。 疫苗生产用到280种原料，来自19个不同国家。如果放弃专利，原料供应链会收到影响。很多不符合生产条件的小公司会开始抢购原料，辉瑞的原料供应将会出现问题，最终导致价格上涨，供应短缺。 辉瑞研发疫苗已经投入了20亿美金的研发费用，准备再增加6亿美金关于Covid 病毒的研究。 Dear Colleagues, The recent announcement that the United States Trade Representative will discuss options to waive some COVID-19 vaccine intellectual property (IP) rights has created some confusion to the world. Has Pfizer done enough to ensure fair and equitable distribution of our COVID-19 vaccine? Is the proposed waiver going to bring solutions or create more problems? I am writing to you today to discuss these questions. Fair and equitable distribution was our North Star from day one. In order to ensure that every country can have access to our COVID-19 vaccine two conditions had to be met: a price that anyone can afford and reliable manufacturing of enough vaccine for all. The first condition was met in the early days. Back in June of 2020 we decided to offer our vaccine through tiered pricing. The wealthier nations would have to pay in the range of about the cost of a takeaway meal and would offer it to their citizens for free. The middle-income countries were offered doses at roughly half that price and the low-income countries were offered doses at cost. Many of the poorest communities will receive their doses through donation. Equity doesn’t mean we give everyone the same. Equity means we give more to those that need more. Meeting the second condition was much more challenging but we are getting there with remarkable speed. Thanks to the ingenuity and hard work of our scientists, engineers and skilled workers, and multibillion dollars of Pfizer investment, we announced that we will provide to the world more than 2.5 billion doses in 2021. In fact, our internal target is 3 billion doses, so we feel quite comfortable about our commitment. Achieving 3 billion doses this year means, by extrapolation, 4 billion doses in 2022.These doses are not for the rich or poor, not for the north or south. These are doses for ALL. We have concluded agreements to supply 116 countries and we are currently in advanced negotiations with many more for a total of approximately 2.7 billion doses in 2021. Upon finalization of all agreements, we expect that 40% of them, or more than 1 billion doses, will go to middle- and low-income countries in 2021. This clearly poses another question. Until today, we have shipped approximately 450 million doses and the balance is more favorable to high income countries. Why is that? When we developed our tiered pricing policy, we reached out to all nations asking them to place orders so we could allocate doses for them. In reality, the high-income countries reserved most of the doses. I became personally concerned with that and I reached out to many heads of middle/low-income countries by letter, phone and even text to urge them to reserve doses because the supply was limited. However, most of them decided to place orders with other vaccine makers either because mRNA technology was untested at that time or because they were offered local production options. Some didn’t even approve our vaccine. Unfortunately, other vaccine producers were not able to meet their supply commitments for varying technical reasons. Most of the countries that did not choose us initially, came back and thanks to our phenomenal supply ramp up, we have started signing supply agreements with them. We expect the supply balance to weigh in their favor in the second half of 2021, and to have virtually enough supply for all in 2022. Last week, I had the opportunity to provide these facts to the US Trade Representative and explain why the suggested waiver of IP rights could only derail this progress. Which brings me to the second question. Is the proposed waiver going to improve the supply situation or create more problems? And my answer is categorically the latter. When we created our vaccine there was no manufacturing production of any mRNA vaccine or medicine anywhere in the world. We had to create manufacturing infrastructure from scratch. With 172 years of quality manufacturing tradition, substantial deployment of capital, and more importantly, an army of highly skilled scientists, engineers and manufacturing workers, we developed in record time the most efficient manufacturing machine of a life-saving vaccine that the world has ever seen. Currently, infrastructure is not the bottleneck for us manufacturing faster. The restriction is the scarcity of highly specialized raw materials needed to produce our vaccine. These 280 different materials or components are produced by many suppliers in 19 different countries. Many of them needed our substantial support (technical and financial) to ramp up their production. Right now, virtually every single gram of raw material produced is shipped immediately into our manufacturing facilities and is converted immediately and reliably to vaccines that are shipped immediately around the world (91 countries to date.) The proposed waiver for COVID-19 vaccines, threatens to disrupt the flow of raw materials. It will unleash a scramble for the critical inputs we require in order to make a safe and effective vaccine. Entities with little or no experience in manufacturing vaccines are likely to chase the very raw materials we require to scale our production, putting the safety and security of all at risk. And I would like to make a final point. I worry that waiving of patent protection will disincentivize anyone else from taking a big risk. We deployed $2 billion before we knew whether we could successfully develop a vaccine because we understood what was at stake. Just recently, I authorized spending an additional $600 million on COVID-19 research and development that will bring our total spend for R&D in 2021 to more than $10 billion . The recent rhetoric will not discourage us from continuing investing in science. But I am not sure if the same is true for the thousands of small biotech innovators that are totally dependent on accessing capital from investors who invest only on the premise that their intellectual property will be protected. Ending the pandemic and vaccinating the world is a massive, but achievable undertaking. We remain fully focused on getting high-quality, safe and effective vaccines to patients all over the world as quickly as possible and to putting an end to this deadly pandemic. Once again, we will not let politics stand in our way and we will continue doing what we do best – creating breakthroughs that change patients’ lives. Albert
谢谢，刚刚去搜了一下，链接在这里，看完了感想就是，这些人为了政治原因进行这种长期不懈的反智宣传，不怕被反噬么。。回头自己的公民不愿意打。。毕竟病毒一直在变异。 EU accuses Russia, China of COVID vaccine disinformation | News | DW | 28.04.2021 EU accuses Russia, China of COVID vaccine disinformation A new EU report found that Beijing and Moscow are seeking to undermine trust in Western coronavirus vaccines — and intensely promoting their own. China and Russia are engaging in campaigns to erode trust in the European Union's coronavirus strategy as well as gin up skepticism of Western-developed coronavirus vaccines, the EU's foreign service said in a report published Wednesday. The report also raised concerns that the countries are using these efforts to particularly exert influence on the Western Balkans. What did the EU say? The findings stem from a report published by the EU External Action Service (EEAS) on disinformation concerning the COVID-19 pandemic. According to the report, "state-sponsored disinformation" efforts have intensified since the beginning of 2021, as vaccine rollouts have started to pick up pace around the world. While China and Russia have increased efforts to promote their own state-produced vaccines, they've been using the promotions to "undermine trust" in Western vaccines and EU institutions. To do this, both countries "are using state-controlled media, networks of proxy media outlets and social media, including official diplomatic social media accounts, to achieve these goals," the report said. In Russia, state media outlets have been trying to "cast doubt" on the European Medicines Agency (EMA) and accusing the body of delaying the approval of the Russian Sputnik V vaccine. China, meanwhile, has been propagating "misleading narratives" about the origins of the coronavirus as well as the safety of certain Western vaccines. A Russian sovereign wealth fund responsible for marketing Sputnik V said the disinformation campaign is actually against Russia and its vaccine. "We will continue to fight disinformation campaign against Sputnik V in the interests of protecting lives around the world and avoiding vaccine monopoly that some vaccine producers may strive for," it said on Twitter. Sowing discontent According to the report, Beijing and Moscow's "vaccine diplomacy" strategies have been particularly targeting the Western Balkans in an effort to exert influence. The report voiced concerns that the rise in coronavirus cases in the bloc and sluggish vaccine rollouts are being spun by Russia and China as examples of a failure of democracy and open societies. Although the EU has been criticized over its slower-than-expected vaccine rollout, the bloc says that a boost in deliveries means it's on track to vaccinate 70% of adults this summer. Still, Hungary broke with the rest of the EU and has been administering vaccines from both Russia and China. In March, the EMA launched a rolling review of Sputnik V. If given the green light, it would be the first non-Western produced coronavirus vaccine to be approved for use in the bloc.
还有就是，Pfizer CEO说的很重要的一点，除了各种安全和质量隐患外，如果真的大家都在开始造，又会面对这些原材料在全世界被分抢，还不如支持现在的药企们赶快生产更多疫苗出来，政治力量的博弈可以慢慢来，疫情可不等人，病毒还在变异，这些才是当前最需要解决的问题。这也是为什么EU主要国家并没有附和Biden，也都在反对逼药企放弃IP。除了昨天默克尔，今天还有更多的反对声音。 Key EU countries rebuff Biden on sharing COVID vaccine patents | Reuters 节选一点： European countries distanced themselves on Friday from a proposal backed by U.S. President Joe Biden to waive patent rights on coronavirus vaccines, arguing that key to ending the COVID-19 pandemic was making and sharing vaccines more quickly. "What is the current issue? It is not really about intellectual property. Can you give intellectual property to laboratories that do not know how to produce and will not produce tomorrow?" Macron said as he went into the summit. European Commission President Ursula von der Leyen echoed that, telling a news conference after the first day of the Porto summit that the EU should be open to a discussion on the patents but sharing the technology was no quick remedy for the pandemic. "In the short and medium term, the IP waiver will not solve the problems, it will not bring a single dose of vaccine in the short and medium term," she told a news conference. Some EU officials argue that it could take two years to agree on the waivers in the World Trade Organization (WTO), most likely making it irrelevant to the current pandemic.
希望大家重点还是看Pfizer CEO说的其他的干货内容。关于政治的那句，Once again, we will not let politics stand in our way and we will continue doing what we do best – creating breakthroughs that change patients’ lives. 我的理解是就事论事，被那么多个国家道德绑架要求放弃知识产权，本来确实也是politics standing in the way of science，他也需要给员工打打士气前行。这种飞来横祸，药企股票掉的，我觉得药企员工们也感觉很委屈吧。
还有就是，Pfizer CEO说的很重要的一点，除了各种安全和质量隐患外，如果真的大家都在开始造，又会面对这些原材料在全世界被分抢，还不如支持现在的药企们赶快生产更多疫苗出来，政治力量的博弈可以慢慢来，疫情可不等人，病毒还在变异，这些才是当前最需要解决的问题。这也是为什么EU主要国家并没有附和Biden，也都在反对逼药企放弃IP。除了昨天默克尔，今天还有更多的反对声音。 Key EU countries rebuff Biden on sharing COVID vaccine patents | Reuters 节选一点： European countries distanced themselves on Friday from a proposal backed by U.S. President Joe Biden to waive patent rights on coronavirus vaccines, arguing that key to ending the COVID-19 pandemic was making and sharing vaccines more quickly. "What is the current issue? It is not really about intellectual property. Can you give intellectual property to laboratories that do not know how to produce and will not produce tomorrow?" Macron said as he went into the summit. European Commission President Ursula von der Leyen echoed that, telling a news conference after the first day of the Porto summit that the EU should be open to a discussion on the patents but sharing the technology was no quick remedy for the pandemic. "In the short and medium term, the IP waiver will not solve the problems, it will not bring a single dose of vaccine in the short and medium term," she told a news conference. Some EU officials argue that it could take two years to agree on the waivers in the World Trade Organization (WTO), most likely making it irrelevant to the current pandemic. Xiaoluojie 发表于 2021-05-07 18:03
一个兽医做啥贡献了？怕不是没压榨科学家就不错了吧，他那年薪可以多给科学家发多少钱哦，可以多雇多少个科学家哦，还不要让politics stand in our way, 他要是没搞办公室政治，一个兽医能当上Pfizer CEO?? 快别恶心人了，明星至少不又当有立。 三观都不一样，我为啥要争取?? 你这么喜欢捧CEO臭脚，才应该赶紧近距离去捧，说不定给你个兽医当当。
CNBC新闻
Today I Sent This Letter To Have a Candid Conversation With Our Colleagues About the Drivers of COVID-19 Access and Availability (linkedin.com) 这是他发在linkedin上面的致全体员工信的全文。提到了很多这两天大家的讨论内容，说上周已经present给过US Trade Representative了。
下面这个是我之前不知道的细节，不知道版上的牛人们之前是不是已经讨论过了：
2020年六月份的时候，Pfizer是提出了tiered pricing，富裕国家就是一份外卖价钱，这样政府可以买单让大家免费打，middle-income的国家是半价，low-income的国家是成本价，然后给很多最穷的地方会直接捐助。然后发生了什么呢？给这些国家提出tiered pricing的时候，问人家下不下订单，富裕国家爽快定了，其他绝大部分都没有，Pfizer很担心，还去一个个找那些非富裕国家的首脑们写信，打电话，甚至发短信，但是： However, most of them decided to place orders with other vaccine makers either because mRNA technology was untested at that time or because they were offered local production options. Some didn’t even approve our vaccine. Unfortunately, other vaccine producers were not able to meet their supply commitments for varying technical reasons. Most of the countries that did not choose us initially, came back and thanks to our phenomenal supply ramp up, we have started signing supply agreements with them. We expect the supply balance to weigh in their favor in the second half of 2021, and to have virtually enough supply for all in 2022.
这就是为什么现在看着疫苗都分配到富裕国家去的原因。
🔥 最新回帖
穷国有时候真的很穷。 买这些东西都是要外汇的。 有些穷国，没啥出口，外汇少得可怜。 我去年还是前年看过文章，说非洲一个国家，一年的外汇才100多美金。但我不记得这个文章写的是哪年的事。
呵呵，不奇怪，去中国注册医疗产品就是想着法要你公开技术要你在中国生产
完全同意，不赚钱的话，过几年等新的病毒出来看谁还搞研发。
🛋️ 沙发板凳
现在又是如下一副嘴脸
https://zhishifenzi.blog.caixin.com/archives/245621
赵佑斌认为，解决疫苗短缺问题需要更科学、更可操作的措施。“比较可行的措施就是技术合作。” 他说，辉瑞、Moderna等公司需要派出技术人员，用成套技术跟发展中国家的药企进行技术合作。他们出技术，其他国家出设备、提供材料，共同生产成立生产疫苗的企业或项目。
更新：转发个122层WIBB的要点总结，写的超好： 要点总结： 2020 年6月开始辉瑞制定了价格体系。具体政策是富裕国价格高，中等国家便宜（基本为富裕国家的一半），穷国成本价，最穷的国家捐赠。 辉瑞开始联系了所有国家让他们提早订货，但只有少数富国下了订单，所以现在的大部分疫苗给了他们。辉瑞又联系了很多中低收入国家，但是大部分中低收入国家都与其他疫苗厂家订了货，辉瑞的MRNA技术也没有得到很多国家批准。但现在其他疫苗出了问题，所以这些国家又返回来订货，21年下半年供应会缓解。 疫苗生产用到280种原料，来自19个不同国家。如果放弃专利，原料供应链会收到影响。很多不符合生产条件的小公司会开始抢购原料，辉瑞的原料供应将会出现问题，最终导致价格上涨，供应短缺。 辉瑞研发疫苗已经投入了20亿美金的研发费用，准备再增加6亿美金关于Covid 病毒的研究。
Dear Colleagues,
The recent announcement that the United States Trade Representative will discuss options to waive some COVID-19 vaccine intellectual property (IP) rights has created some confusion to the world. Has Pfizer done enough to ensure fair and equitable distribution of our COVID-19 vaccine? Is the proposed waiver going to bring solutions or create more problems? I am writing to you today to discuss these questions.
Fair and equitable distribution was our North Star from day one. In order to ensure that every country can have access to our COVID-19 vaccine two conditions had to be met: a price that anyone can afford and reliable manufacturing of enough vaccine for all.
The first condition was met in the early days. Back in June of 2020 we decided to offer our vaccine through tiered pricing. The wealthier nations would have to pay in the range of about the cost of a takeaway meal and would offer it to their citizens for free. The middle-income countries were offered doses at roughly half that price and the low-income countries were offered doses at cost. Many of the poorest communities will receive their doses through donation. Equity doesn’t mean we give everyone the same. Equity means we give more to those that need more.
Meeting the second condition was much more challenging but we are getting there with remarkable speed. Thanks to the ingenuity and hard work of our scientists, engineers and skilled workers, and multibillion dollars of Pfizer investment, we announced that we will provide to the world more than 2.5 billion doses in 2021. In fact, our internal target is 3 billion doses, so we feel quite comfortable about our commitment. Achieving 3 billion doses this year means, by extrapolation, 4 billion doses in 2022. These doses are not for the rich or poor, not for the north or south. These are doses for ALL. We have concluded agreements to supply 116 countries and we are currently in advanced negotiations with many more for a total of approximately 2.7 billion doses in 2021. Upon finalization of all agreements, we expect that 40% of them, or more than 1 billion doses, will go to middle- and low-income countries in 2021.
This clearly poses another question. Until today, we have shipped approximately 450 million doses and the balance is more favorable to high income countries. Why is that? When we developed our tiered pricing policy, we reached out to all nations asking them to place orders so we could allocate doses for them. In reality, the high-income countries reserved most of the doses. I became personally concerned with that and I reached out to many heads of middle/low-income countries by letter, phone and even text to urge them to reserve doses because the supply was limited. However, most of them decided to place orders with other vaccine makers either because mRNA technology was untested at that time or because they were offered local production options. Some didn’t even approve our vaccine. Unfortunately, other vaccine producers were not able to meet their supply commitments for varying technical reasons. Most of the countries that did not choose us initially, came back and thanks to our phenomenal supply ramp up, we have started signing supply agreements with them. We expect the supply balance to weigh in their favor in the second half of 2021, and to have virtually enough supply for all in 2022.
Last week, I had the opportunity to provide these facts to the US Trade Representative and explain why the suggested waiver of IP rights could only derail this progress. Which brings me to the second question. Is the proposed waiver going to improve the supply situation or create more problems? And my answer is categorically the latter.
When we created our vaccine there was no manufacturing production of any mRNA vaccine or medicine anywhere in the world. We had to create manufacturing infrastructure from scratch. With 172 years of quality manufacturing tradition, substantial deployment of capital, and more importantly, an army of highly skilled scientists, engineers and manufacturing workers, we developed in record time the most efficient manufacturing machine of a life-saving vaccine that the world has ever seen. Currently, infrastructure is not the bottleneck for us manufacturing faster. The restriction is the scarcity of highly specialized raw materials needed to produce our vaccine. These 280 different materials or components are produced by many suppliers in 19 different countries. Many of them needed our substantial support (technical and financial) to ramp up their production. Right now, virtually every single gram of raw material produced is shipped immediately into our manufacturing facilities and is converted immediately and reliably to vaccines that are shipped immediately around the world (91 countries to date.) The proposed waiver for COVID-19 vaccines, threatens to disrupt the flow of raw materials. It will unleash a scramble for the critical inputs we require in order to make a safe and effective vaccine. Entities with little or no experience in manufacturing vaccines are likely to chase the very raw materials we require to scale our production, putting the safety and security of all at risk.
And I would like to make a final point. I worry that waiving of patent protection will disincentivize anyone else from taking a big risk. We deployed $2 billion before we knew whether we could successfully develop a vaccine because we understood what was at stake. Just recently, I authorized spending an additional $600 million on COVID-19 research and development that will bring our total spend for R&D in 2021 to more than $10 billion . The recent rhetoric will not discourage us from continuing investing in science. But I am not sure if the same is true for the thousands of small biotech innovators that are totally dependent on accessing capital from investors who invest only on the premise that their intellectual property will be protected.
Ending the pandemic and vaccinating the world is a massive, but achievable undertaking. We remain fully focused on getting high-quality, safe and effective vaccines to patients all over the world as quickly as possible and to putting an end to this deadly pandemic. Once again, we will not let politics stand in our way and we will continue doing what we do best – creating breakthroughs that change patients’ lives.
Albert
👍
上周EU有谴责Moscow & Beijing，说他们在媒体上抹黑西方疫苗。这个新闻huaren上好像没转。
呵呵🤭听听就行了。。
他的奖金和公司财富状况挂钩吧。这个疫苗应该为他们赚了不少钱。。
然后盈利自己拿大头，当别人都是傻子呢
对的对的，这个心理其实也可以理解，但是最开始给他们多次机会不下单，现在反过来集体抱怨都分发到了富裕国家，就实在。。。。。
或者就想大家下次都没药 我过不好你也别想过好
做疫苗赚钱有什么不对，不让人家赚钱以后谁给你做疫苗？谁给你做药？谁给你做医疗器材？
赚钱有什么不对吗? 他们就该赚钱，而且赚大钱。 凭什么人家就得无偿奉献，连成本都不给人家? 自己那么能，用爱发电来免疫新冠吧
疫苗赚钱没有什么不对。支持不放弃IP。 但这个CEO说把政治放一边，就虚伪了。。CEO对政治盯得可紧了
你完全了解错了我的意思。我不是说赚钱和放弃IP的事，是说CEO的那句话虚伪。
比起tech公司暴利，药厂真的赚的都算辛苦钱了
这个疫苗是给他们挣钱了，可是每个公司也有投入很多钱，最后没成功的药，公司就靠这些成功的药物盈利去贴补那些失败的药物
谢谢，刚刚去搜了一下，链接在这里，看完了感想就是，这些人为了政治原因进行这种长期不懈的反智宣传，不怕被反噬么。。回头自己的公民不愿意打。。毕竟病毒一直在变异。 EU accuses Russia, China of COVID vaccine disinformation | News | DW | 28.04.2021
EU accuses Russia, China of COVID vaccine disinformation A new EU report found that Beijing and Moscow are seeking to undermine trust in Western coronavirus vaccines — and intensely promoting their own.
China and Russia are engaging in campaigns to erode trust in the European Union's coronavirus strategy as well as gin up skepticism of Western-developed coronavirus vaccines, the EU's foreign service said in a report published Wednesday. The report also raised concerns that the countries are using these efforts to particularly exert influence on the Western Balkans.
What did the EU say? The findings stem from a report published by the EU External Action Service (EEAS) on disinformation concerning the COVID-19 pandemic. According to the report, "state-sponsored disinformation" efforts have intensified since the beginning of 2021, as vaccine rollouts have started to pick up pace around the world.
While China and Russia have increased efforts to promote their own state-produced vaccines, they've been using the promotions to "undermine trust" in Western vaccines and EU institutions.
To do this, both countries "are using state-controlled media, networks of proxy media outlets and social media, including official diplomatic social media accounts, to achieve these goals," the report said. In Russia, state media outlets have been trying to "cast doubt" on the European Medicines Agency (EMA) and accusing the body of delaying the approval of the Russian Sputnik V vaccine.
China, meanwhile, has been propagating "misleading narratives" about the origins of the coronavirus as well as the safety of certain Western vaccines.
A Russian sovereign wealth fund responsible for marketing Sputnik V said the disinformation campaign is actually against Russia and its vaccine. "We will continue to fight disinformation campaign against Sputnik V in the interests of protecting lives around the world and avoiding vaccine monopoly that some vaccine producers may strive for," it said on Twitter.
Sowing discontent
According to the report, Beijing and Moscow's "vaccine diplomacy" strategies have been particularly targeting the Western Balkans in an effort to exert influence. The report voiced concerns that the rise in coronavirus cases in the bloc and sluggish vaccine rollouts are being spun by Russia and China as examples of a failure of democracy and open societies. Although the EU has been criticized over its slower-than-expected vaccine rollout, the bloc says that a boost in deliveries means it's on track to vaccinate 70% of adults this summer. Still, Hungary broke with the rest of the EU and has been administering vaccines from both Russia and China.
In March, the EMA launched a rolling review of Sputnik V. If given the green light, it would be the first non-Western produced coronavirus vaccine to be approved for use in the bloc.
这若算虚伪也比直接下跪好
还能更不要脸一点儿么
任何一个穷国都出的起这个钱，也就是当权者第十八个小老婆的首饰费用而已，不想出有什么办法
脸真大，黑了人家一年了，现在一看效果不错，马上说来来来，为了人类健康，快过来免费教我怎么生产。
五毛横行，这种新闻怎么会转
我觉得就是跟自己员工解释一下，坦荡示人，虽然他不欠任何人一个解释。
你还是去研究blinds和一亩三分地吧，看你这点眼界
然后翻脸不认人，跟乙肝疫苗一样，前中国没几个知道是Merck 白给的，天天叉着腰骂美国人
对于一个可以生产出救千万生命的药厂，怎么赚钱都不为过。 况且药厂有很多没有成功的药物研究都是巨额的前期投入，这部分损失都是靠这些能赚钱的药来补贴的。 你觉得哪里有问题？
吃大户呀，历史一贯作风
知道也觉得merck占了便宜，为了中国市场
作为一个马工，我也这么觉得，科学技术工作者真的应该提高待遇
人家有关国门这一绝招
所以美国也是傻啊，被这么多不要脸的国家用政治正确来要挟。 看看大爱无疆的左派默老太，也反对这个提议。
的确没你随随便便几个米眼界高。。俺生活在贫困线以下的贫下中农没办法和你高大上的比。。
哪个CEO没有受政策导向影响？特别是这个CEO，去年不知道在msm采访和发表了多少讲话，现在说不管政治了？
企业就是要盈利，不放弃IP，完全支持！一定要加一句表明自己觉悟高和政治无关。呵呵。。
然后还叫着国产疫苗总出问题肯定是Merck留了后手。人家教了你，你自己偷工减料，怨谁呀
支持赚钱，不放弃IP。
但一个CEO，去年不知道在msm采访和发表了多少讲话，现在说不管政治了，加这句话就虚伪。。还不如，大大方方的说企业有盈利，要对股民和员工负责，这样没有任何问题。
你这种揪着一句话来佐证自己政治立场而不是就事论事的作风不改改，以后工作上吃亏的是你自己
Key EU countries rebuff Biden on sharing COVID vaccine patents | Reuters 节选一点： European countries distanced themselves on Friday from a proposal backed by U.S. President Joe Biden to waive patent rights on coronavirus vaccines, arguing that key to ending the COVID-19 pandemic was making and sharing vaccines more quickly.
"What is the current issue? It is not really about intellectual property. Can you give intellectual property to laboratories that do not know how to produce and will not produce tomorrow?" Macron said as he went into the summit.
European Commission President Ursula von der Leyen echoed that, telling a news conference after the first day of the Porto summit that the EU should be open to a discussion on the patents but sharing the technology was no quick remedy for the pandemic. "In the short and medium term, the IP waiver will not solve the problems, it will not bring a single dose of vaccine in the short and medium term," she told a news conference.
Some EU officials argue that it could take two years to agree on the waivers in the World Trade Organization (WTO), most likely making it irrelevant to the current pandemic.
你的理解能力有问题，人的意思是不能迫于政治上的压力就当了傻白甜，有啥问题？
你读出我在那个回复有什么政治立场了？你是不是脑补的有点多了。。
我就说了不认同CEO的一句话，你就推测出这么多东西，还包括我工作吃亏。。你牛🐂B！
Pfizer从来不是以道德闻名的。他最有名的历史是停了其他药的生产线去生产伟哥，造成救命药品短缺。 我也同意开发疫苗专利是杀鸡取卵。
开放专利，手把手的去教，造成原材料挤兑，美国两个亿的人没打呢，最后结果难说。出于对美国志愿者的尊重，也不能越厨代庖，拜登以后说话要有分寸。
So？ 疫苗也救了很多人，研发不要钱么？科学家们就该白白贡献？层主这种只会呵呵的说风凉话的人又做了什么呢？
中国疫苗更贵。。。。
希腊兽医。。。能有什么格局呢？自己捞钱最重要。
有这历史的链接么，google了半天没找到，纯好奇。。
奇了怪了，人家研发出了疫苗为什么不能赚钱，圣母白莲花真是让人反胃，合着药企就该是活菩萨
给科学家付了多少钱？买的起房了吗？辉瑞希腊兽医CEO三年前年薪就2800万美金了，科学家怕是下辈子也赚不到把。 一到捞钱就把科学家的摆出来，呵呵呵，可笑之极。
So? 有多少人能当CEO的，如果你觉得自己有这个本事也可以去争取啊，看有没有公司愿意雇你了。这些大CEO管理的公司对人类社会也是做出贡献了，一年28M税前乘6.5正好1.8忆（一个爽），国内明星一部戏（拍摄用不了一年哦）的价格，你觉得哪个更畸形呢
这个确实 优良原材料给了其他地方，都不知道生产质量如何，就真是浪费了 Biden政府以为生产疫苗是写几个字的事情吗
一个兽医做啥贡献了？怕不是没压榨科学家就不错了吧，他那年薪可以多给科学家发多少钱哦，可以多雇多少个科学家哦，还不要让politics stand in our way, 他要是没搞办公室政治，一个兽医能当上Pfizer CEO?? 快别恶心人了，明星至少不又当有立。
三观都不一样，我为啥要争取?? 你这么喜欢捧CEO臭脚，才应该赶紧近距离去捧，说不定给你个兽医当当。
根本不相信其他国家的质量检控。
希望别人做雷锋，自己搭便车呗
奖金和公司财富状况 是他们应该得的。 如果免费给出去，那将来没有公司愿意投资开放疫苗了。反正开发出来也是免费的。对公司，员工没帮助。
赞成，不然以后谁有干劲去研发
观点不同很正常，讨论一定要发展到人身攻击有什么意思呢？展览素质么？ 你看清楚我写的“这些大CEO管理的公司”, 主语是公司不是CEO，动词是贡献。能管理大型跨国公司，就是一种能力证明，这有什么可抬杠的呢。我没有这个本事，你不用攻击我。曾经是什么背景和能力有什么关系呢？难道别人会说爱因斯坦不过一个曾经专利局的小公务员，他提出的理论有什么可信度么。 你说明星不又当又立就太可笑了，之前大把明星跟风发博说自己高危职业，熬夜危险，这不是又当又立么，不是被群嘲了么
赞！很合理。公益组织可以筹划给穷的地方捐疫苗。
复星连灌装都出现密封性不好的问题。
这人不知道受什么刺激了，看人家赚钱多就心态失衡了。药是辉瑞做的，ceo当然有功劳，又不是只有实验室里做科研的才算。还谈什么三观……🤮
吃瓜群众觉得作为ceo，人家能在大的public health crisis时候搞出疫苗就很赞了，值得这么多工资。
绝对一个大SB.
扯蛋，ｇｅ 的老总前２天还企图给自己开２４０M 的工资呢
２８M 这么大的公司不算离谱了
网上随便一查，去年是21M，前年不到20M
估计家里人是千老
波音那个前CEO 被赶走还拿了６５M呢
你可以说这个不合理，但是现在就这行情，他不做辉瑞的头头去其他地方也是香饽饽能拿那么多
人家明星说的自己没毛病啊。公司管理层CEO只管捞钱为自家做贡献，为巨富做贡献差不多吧。从你嘴里直接上升到为人类做贡献？为人类作了哪门子贡献？一边自己每年几千万进钱包，美国几千万人又因为医疗账单破产了。科学家愿意被他代表吗？可笑的很，还动不动就科学家要吃饭，科学家自己买的豪宅吃的起品牌药了吗？
哈哈哈，玩儿自私自利给自己捞钱又当又立的时候，就大嘴一张科学家长科学家短科学家也要买房过日子，转身就给科学家安个侮辱性的称呼，脸可真大啊。
嗯，现在随便一个大公司的CEO都是这个薪水。
自己公民不愿意打，美华英文不好的天天看微信和国内消息的一样不敢打，我觉得挺好的，反正都是自己的信仰和选择
这叫共产主义精神，明明说了不忘初心，你以为是啥初心
revenue疫苗肯定占了大头，但赚不赚钱很难说。药厂不像高科技公司，profit margin非常小。基本能收支平衡就很好了。
为啥药厂利润低？
下次sars3.0时候，你不等资本家给你造疫苗？
不要那么短视啊 药企也要继续抗击癌症和17年后的sars3